Adjuvants for peptide-based cancer vaccines

Cancer therapies based on T cells have shown impressive clinical benefit. In particular, immune checkpoint blockade therapies with anti-CTLA-4 and anti-PD-1/PD-L1 are causing dramatic tumor shrinkage and prolonged patient survival in a variety of cancers. However, many patients do not benefit, possi...

Descripción completa

Detalles Bibliográficos
Autores principales: Khong, Hiep, Overwijk, Willem W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5028954/
https://www.ncbi.nlm.nih.gov/pubmed/27660710
http://dx.doi.org/10.1186/s40425-016-0160-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5028954/
https://www.ncbi.nlm.nih.gov/pubmed/27660710
http://dx.doi.org/10.1186/s40425-016-0160-y

Ejemplares similares